New stroke drug shows promise in early safety trial

NCT ID NCT00821821

Completed Disease control Sponsor: Shionogi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study tested a drug called Edaravone (MCI-186) in 36 people who had an acute ischemic stroke. The goal was to check the drug's safety and how the body processes it. Participants received either Edaravone or a placebo through an IV over 72 hours. The trial was completed, but it was too small to determine if the drug improves stroke recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Edaravone (MCI-186)
What this could lead to: If successful, this could point toward a treatment to limit brain damage after a stroke.
What could go wrong: This is a small, early-phase trial focused on safety and drug levels, not on proving the drug works. The results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE (AIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE (AIS)

Contacts and locations

Locations

Erasmus Medical Center

Rotterdam, Netherlands
Helsinki University Central Hospital

Helsinki, Finland
Newcastle upon Tyne Hospitals NHS Foundation Trust

Newcastle, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.